Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349392 | 0.87 | ALDH1A1 (0.51) | ALDH1A1POLBSMN1; SMN2PTGDR2 | |
| SCHEMBL14787928 | 0.85 | ALDH1A1 (0.63) | ALDH1A1POLBSMN1; SMN2PTGDR2KDM4E | |
| SCHEMBL1949360 | 0.84 | ALDH1A1 (0.56) | ALDH1A1POLBSMN1; SMN2KDM4ELMNA | |
| SCHEMBL22085676 | 0.83 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2TSHRKDM4E | |
| SCHEMBL29956334 | 0.83 | POLB (0.65) | ALDH1A1POLBSMN1; SMN2TSHRKDM4E | |
| SCHEMBL5246469 | 0.83 | POLB (0.65) | ALDH1A1POLBSMN1; SMN2TSHRKDM4E | |
| SCHEMBL6536289 | 0.83 | POLB (0.74) | ALDH1A1POLBSMN1; SMN2TSHRKDM4E | |
| SCHEMBL7282745 | 0.82 | ALDH1A1 (0.66) | ALDH1A1POLBSMN1; SMN2PTGDR2KDM4E | |
| SCHEMBL7390751 | 0.81 | ALDH1A1 (0.76) | ALDH1A1POLBSMN1; SMN2KDM4EFDPS | |
| SCHEMBL528365 | 0.81 | POLB (0.48) | ALDH1A1POLBSMN1; SMN2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595665-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| CN-103052406-A | Bifunctional rho kinase inhibitor compounds, compositions and uses | INSPIRE PHARMACEUTICALS INC | 2013-04-17 | — | — | CN | disclosed |
| WO-2012012282-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK2, ROCK1, RHOA | ALDH1A1 4514/4885POLB 1684/4885SMN1; SMN2 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.